Express Pharma

Dermatology space to benefit most from five potential blockbusters


According to GBI Research, Dupixent is expected to face very little competition and as a result will generate the second highest revenue of any drug in the therapy area

Since 2014, five potential blockbuster drugs have been approved in the dermatology therapy area, within which they are forecast to achieve aggregate annual revenue of $12.4 billion by 2023, according to GBI Research.

The company’s latest report states that four of the five market-driving drugs — Cosentyx, Otezla, Eucrisa and Taltz — were approved for psoriasis, and one,